Posaconazole: when and how? The clinician’s view
- 18 July 2011
- Vol. 55 (2), 110-122
- https://doi.org/10.1111/j.1439-0507.2011.02061.x
Abstract
Posaconazole is the newest triazole antifungal agent available as an oral suspension with an extended spectrum of activity against Candida species, Aspergillus species, Cryptococcus neoformans, Zygomycetes and endemic fungi. Among posaconazole advantages are the relatively low potential of cross-resistance with other azoles, few drug interactions compared with other azoles and its activity against Zygomycetes. Randomised, double-blind trials have shown that posaconazole is effective for prophylaxis against invasive fungal infections (IFI), especially aspergillosis, in high-risk patients. Results of Phase III clinical trials and case/series reports indicate that posaconazole is effective in treating oesophageal candidiasis, including azole-refractory disease, and other IFI refractory to standard antifungal therapies. To date, posaconazole has appeared to be well tolerated even in long-term courses; it has an excellent safety profile with gastrointestinal disturbances being the most common adverse events reported. The dose of posaconazole is 200 mg three times daily for prophylaxis, 800 mg daily in two or four divided doses for the treatment of IFI and 100 mg daily (200 mg loading dose) for the treatment of oropharyngeal candidiasis. On the basis of early clinical experience, it appears that posaconazole will be a valuable aid in the management of life-threatening fungal infections.This publication has 96 references indexed in Scilit:
- The changing face of epidemiology of invasive fungal disease in EuropeMycoses, 2009
- Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapyBone Marrow Transplantation, 2007
- Epidemiology of Invasive Candidiasis: a Persistent Public Health ProblemClinical Microbiology Reviews, 2007
- Posaconazole: a broad-spectrum triazole antifungalThe Lancet Infectious Diseases, 2005
- In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance programDiagnostic Microbiology and Infectious Disease, 2004
- Three-Dimensional Models of Wild-Type and Mutated Forms of Cytochrome P450 14α-Sterol Demethylases from Aspergillus fumigatus and Candida albicans Provide Insights into Posaconazole BindingAntimicrobial Agents and Chemotherapy, 2004
- Infections due to emerging and uncommon medically important fungal pathogensClinical Microbiology & Infection, 2004
- In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. and Cryptococcus neoformansAntimicrobial Agents and Chemotherapy, 2001
- Trends in Mortality Due to Invasive Mycotic Diseases in the United States, 1980–1997Clinical Infectious Diseases, 2001
- Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida sppAntimicrobial Agents and Chemotherapy, 1997